DOCSLIB.ORG

Dawn of Early Detection Healthcare

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Dawn of early OVERVIEW EARLY DETECTION THE BARRIERdetection healthcare BREAKING THROUGH T H E T E C H N A N O X A R C NANOX BENEFITS R S N A 2 0 2 0 OPINIONS O U R P L A N BUSINESS MODEL DEPLOYMENTS NANOX CLOUD FDA PARTNERSHIPS Investor Presentation T E A M S U M M A R Y April 2021 1 Forward-Looking Information Statement also affect these forward-looking statements. The reader should not place undue Statements contained in this presentation concerning expectations, beliefs, plans, reliance on any forward-looking statements included in this presentation. These objectives, goals, strategies, future events or performance and underlying statements speak only as of the date made and Nanox is under no obligation and assumptions and other statements that are other than statements of historical fact disavows any obligation to update or revise such statements as a result of any are “forward-looking statements.” These statements often include words such as event, circumstances or otherwise, unless required by applicable legislation or “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “target,” “project,” regulation. “forecast,” “seek,” “will,” “may,” “should,” “could,” “would” or similar expressions. Although Nanox believes that the expectations and assumptions reflected in these These risks and uncertainties are described more fully under the caption ”Risk statements are reasonable, these expectations or forecasts of future performance Factors” in the Company’s registration statement relating to this offering and other may not prove to be correct. Forward-looking statements are subject to many risks filings with the Securities and Exchange Commission. Other risks and uncertainties of and uncertainties, and actual results may differ materially from the results discussed which the Company is not currently aware may also affect Company’s forward- in forward-looking statements. The following are among the important factors that looking statements. The reader should not place undue reliance on any forward- could cause actual results to differ materially from the forward-looking statements: looking statements included in this presentation. These statements speak only as of risks related to Nanox’s ability to successfully demonstrate the feasibility of its the date made and the Company is under no obligation and disavows any technology for commercial applications; Nanox’s expectations regarding the obligation to update or revise such statements as a result of any event, necessity of, timing of filing for, and receipt and maintenance of, regulatory circumstances or otherwise, unless required by applicable legislation or regulation. clearances or approvals regarding its X-Ray source technology and the Nanox.ARC from regulatory agencies worldwide and its ongoing compliance with applicable Market and Industry Data and Customer Information quality standards and regulatory requirements; Nanox’s ability to enter into and This presentation has been prepared by Nanox and includes market data and other maintain commercially reasonable arrangements with third-party manufacturers information from sources believed by the company to be reliable. For example, and suppliers to manufacture the Nanox.ARC; the market acceptance of the industry and market data, including Nanox’s own research, and surveys or industry Nanox.ARC and the proposed pay-per-scan business model; Nanox’s expectations publications and surveys as well as public information about Nanox’s customers and regarding collaborations with third-parties and their potential benefits; Nanox’s discussion with them. Some data are also based on Nanox’s good-faith estimates, ability to conduct business globally; the impact of general economic conditions, which are derived from Nanox’s review of internal sources as well as the other general conditions in the medical technology and imaging industries; the impact of sources described above. Although Nanox believes these sources are reliable, the COVID-19 pandemic on the Company's business operations; changes in the Nanox has not independently verified the information is accurate and complete. As global and regional regulatory environments in the jurisdictions in which Nanox does a result, you should be aware that market share, ranking and other similar data set or plans to do business; and market volatility, fluctuations in costs and changes to forth in this presentation, and estimates and beliefs based on such data may not be the competitive environment, among others. Consequently, actual future results reliable. may differ materially from the anticipated results expressed in the forward-looking statements. Other risks and uncertainties of which Nanox is not currently aware may 2 Nanox at a glance The What Unmet need Game changing tech Disruptive business model Nanox aims to build a Large deficit of medical Nanox’s novel digital X-Ray source Executed contracts for 5,150 units ILLUSTRATIVE MODEL global infrastructure for imaging systems due to high replaces an analog X-Ray that has been pending regulatory and other medical imaging system costs used for over 100 years and enables approvals POTENTIAL ANNUAL RECURRING REVENUE ASSUMING THE 5,150 significant cost reduction CONTRACTED UNITS ARE DEPLOYED AND OPERATIONAL Medical Screening as a Service $1,194,000,000 Utilizing innovative, patent (MSaaS) opens a recurring protected and disruptive Developing a new breed of medical revenue model that has the technology, Nanox can offer imaging infrastructure that can be potential to provide substantial medical technology that potentially deployed in mass due to revenues expands access, resulting in significantly lower costs and a small $397,000,000 better outcomes and lower footprint, coupled with a radiology costs. services cloud platform $139,000,000 Planning global mass 7 20 60 SCANS PER DAY Upcoming Milestones deployment of 15,000 systems with a Pay-per- Until today, technology was Scan subscription the barrier to medical model imaging availability. We are targeting several near-term value catalysts such as FDA approvals and commercialization See slide 27 for full detail and assumptions Nanox believes it has broken that barrier. Strategic partner deals signed First units shipped by Q1 2022 Concept device. Manufacturing ramp-up FDA single source and multi For educational purposes With global execution source device approvals 2/3 of the world’s population Global deployments only. expected to start this year has no meaningful access to Nanox invites partners to join medical imaging. 15,000 units the potentially next Strategic Shareholders deployed and operational revolution in Weeks and months of wait 2021 preventive healthcare. times for radiology Exceptionally seasoned execution diagnostics results. 2022-2024 team Healthcare and technology veterans from companies like GE, Philips, and highly successful, game-changing technology entrepreneurs 3 Preventive screening OVERVIEW EARLY DETECTION Early detection is key to THE BARRIER BREAKING THROUGH T H E T E C H preventive healthcare. N A N O X A R C NANOX BENEFITS R S N A 2020 Treatable conditions, such as cancer, cardiovascular OPINIONS failures and others are often diagnosed too late. O U R P L A N BUSINESS MODEL DEPLOYMENTS NANOX CLOUD FDA PARTNERSHIPS T E A M S U M M A R Y 4 Early detection remains theoretical OVERVIEW EARLY DETECTION 2/3 of the world’s THE BARRIER BREAKING THROUGH T H E T E C H population have no N A N O X A R C NANOX BENEFITS meaningful access to R S N A 2020 OPINIONS medical imaging O U R P L A N BUSINESS MODEL DEPLOYMENTS The majority of the remaining 1/3 suffer NANOX CLOUD from weeks and months of wait time for FDA PARTNERSHIPS access to medical scanners and T E A M diagnostic results. S U M M A R Y 5 Why? OVERVIEW EARLY DETECTION Medical imaging THE BARRIER BREAKING THROUGH T H E T E C H systems are too N A N O X A R C NANOX BENEFITS expensive and R S N A 2020 OPINIONS complex for mass O U R P L A N BUSINESS MODEL deployment. DEPLOYMENTS NANOX CLOUD FDA PARTNERSHIPS T E A M S U M M A R Y 6 The key inhibitor OVERVIEW EARLY DETECTION X-Ray source technology THE BARRIER BREAKING THROUGH T H E T E C H has not changed since its N A N O X A R C NANOX BENEFITS discovery over 120 years R S N A 2020 OPINIONS ago O U R P L A N BUSINESS MODEL DEPLOYMENTS NANOX CLOUD FDA PARTNERSHIPS T E A M S U M M A R Y 7 Wilhelm Conrad Röntgen The hot cathode OVERVIEW EARLY DETECTION Current day X-Ray tube THE BARRIER Analog X-Ray source BREAKING THROUGH T H E T E C H Heats up a metal filament to 2,000° Celsius to produce the N A N O X A R C electron streams necessary for NANOX BENEFITS X-Ray emission R S N A 2020 OPINIONS Electrons O U R P L A N BUSINESS MODEL DEPLOYMENTS NANOX CLOUD FDA PARTNERSHIPS T E A M S U M M A R Y 8 Main contributor to high-cost of imaging systems OVERVIEW EARLY DETECTION THE BARRIER BREAKING THROUGH T H E T E C H N A N O X A R C NANOX BENEFITS R S N A 2020 OPINIONS O U R P L A N BUSINESS MODEL The legacy DEPLOYMENTS analog X-Ray NANOX CLOUD FDA source PARTNERSHIPS Requires extremely high-voltage, complex T E A M mechanics and special cooling to produce the S U M M A R Y electrons needed for X-Ray emission, resulting in an average $150,000 cost for the source alone 9 The Nanox paradigm OVERVIEW EARLY DETECTION Driving higher THE BARRIER rates of medical BREAKING THROUGH Which we expect will prevention through T H E T E C H enable significantly early-detection. N A N O X A R C higher availability of NANOX BENEFITS Will result in lower cost R S N A 2020 imaging services A
Recommended publications
  • Celebrating 20 Years of SPECT/CT the Introduction of Hawkeye, the World’S First Hybrid Imaging System

    Celebrating 20 Years of SPECT/CT the Introduction of Hawkeye, the World’S First Hybrid Imaging System

    CLINICAL VALUE HAWKEYE SPECT/CT Celebrating 20 Years of SPECT/CT The introduction of Hawkeye, the world’s first hybrid imaging system Nearly 20 years ago, a pivotal event shaped the future of The unclear medicine nuclear medicine. Once called the “unclear medicine,” nuclear Invented by Hal O. Anger in the mid-1950s, nuclear medicine medicine was forever changed with the introduction of cameras detect gamma radiation to depict metabolic Hawkeye, the world’s first clinical hybrid imaging system. processes within a living body. While gamma cameras helped GE Healthcare (at that time known as GE Medical Systems) revolutionize the field of functional medical imaging, there was introduced Hawkeye, a dual-modality SPECT and CT system, at one key limitation: the lack of anatomical markers in the image. the 1999 Society of Nuclear Medicine (SNM) Annual Meeting, heralding in a new era of “more clear medicine.” “We always understood that we needed anatomical and structural data to provide the best details and a precise answer to the clinical question,” says Ora Israel, MD, Director Emeritus of Nuclear Medicine/PET (retired) at Rambam Healthcare Campus, Haifa, Israel. She recalls using fiducial markers placed on the patient’s body to identify the location of key anatomical areas, such as the chest or abdomen. In some cases, Professor Israel and her colleagues would try to repeat the nuclear medicine study on a CT with the patient in the same position. It was a difficult and time-consuming process that she says never really worked well. “There was a clear purpose to improve the specificity of nuclear medicine by defining the anatomical relationship between isotope imaging and anatomy,” says Martin Sandler, MD, Professor of Radiology and Radiological Sciences and formerly Chairman of the Department of Radiology and Radiological Sciences at Vanderbilt University School of Medicine.
  • Market Cap Close ADV 1598 67Th Pctl 745,214,477.91 $ 23.96

    Market Cap Close ADV 1598 67Th Pctl 745,214,477.91 $ 23.96

    Market Cap Close ADV 1598 67th Pctl $ 745,214,477.91 $ 23.96 225,966.94 801 33rd Pctl $ 199,581,478.89 $ 10.09 53,054.83 2399 Ticker_ Listing_ Effective_ Revised Symbol Security_Name Exchange Date Mkt Cap Close ADV Stratum Stratum AAC AAC Holdings, Inc. N 20160906 M M M M-M-M M-M-M AAMC Altisource Asset Management Corp A 20160906 L M L L-M-L L-M-L AAN Aarons Inc N 20160906 H H H H-H-H H-H-H AAV Advantage Oil & Gas Ltd N 20160906 H L M H-L-M H-M-M AB Alliance Bernstein Holding L P N 20160906 H M M H-M-M H-M-M ABG Asbury Automotive Group Inc N 20160906 H H H H-H-H H-H-H ABM ABM Industries Inc. N 20160906 H H H H-H-H H-H-H AC Associated Capital Group, Inc. N 20160906 H H L H-H-L H-H-L ACCO ACCO Brand Corp. N 20160906 H L H H-L-H H-L-H ACU Acme United A 20160906 L M L L-M-L L-M-L ACY AeroCentury Corp A 20160906 L L L L-L-L L-L-L ADK Adcare Health System A 20160906 L L L L-L-L L-L-L ADPT Adeptus Health Inc. N 20160906 M H H M-H-H M-H-H AE Adams Res Energy Inc A 20160906 L H L L-H-L L-H-L AEL American Equity Inv Life Hldg Co N 20160906 H M H H-M-H H-M-H AF Astoria Financial Corporation N 20160906 H M H H-M-H H-M-H AGM Fed Agricul Mtg Clc Non Voting N 20160906 M H M M-H-M M-H-M AGM A Fed Agricultural Mtg Cla Voting N 20160906 L H L L-H-L L-H-L AGRO Adecoagro S A N 20160906 H L H H-L-H H-L-H AGX Argan Inc N 20160906 M H M M-H-M M-H-M AHC A H Belo Corp N 20160906 L L L L-L-L L-L-L AHL ASPEN Insurance Holding Limited N 20160906 H H H H-H-H H-H-H AHS AMN Healthcare Services Inc.
  • NASDAQ Stock Market

    NASDAQ Stock Market

    Nasdaq Stock Market Friday, December 28, 2018 Name Symbol Close 1st Constitution Bancorp FCCY 19.75 1st Source SRCE 40.25 2U TWOU 48.31 21st Century Fox Cl A FOXA 47.97 21st Century Fox Cl B FOX 47.62 21Vianet Group ADR VNET 8.63 51job ADR JOBS 61.7 111 ADR YI 6.05 360 Finance ADR QFIN 15.74 1347 Property Insurance Holdings PIH 4.05 1-800-FLOWERS.COM Cl A FLWS 11.92 AAON AAON 34.85 Abiomed ABMD 318.17 Acacia Communications ACIA 37.69 Acacia Research - Acacia ACTG 3 Technologies Acadia Healthcare ACHC 25.56 ACADIA Pharmaceuticals ACAD 15.65 Acceleron Pharma XLRN 44.13 Access National ANCX 21.31 Accuray ARAY 3.45 AcelRx Pharmaceuticals ACRX 2.34 Aceto ACET 0.82 Achaogen AKAO 1.31 Achillion Pharmaceuticals ACHN 1.48 AC Immune ACIU 9.78 ACI Worldwide ACIW 27.25 Aclaris Therapeutics ACRS 7.31 ACM Research Cl A ACMR 10.47 Acorda Therapeutics ACOR 14.98 Activision Blizzard ATVI 46.8 Adamas Pharmaceuticals ADMS 8.45 Adaptimmune Therapeutics ADR ADAP 5.15 Addus HomeCare ADUS 67.27 ADDvantage Technologies Group AEY 1.43 Adobe ADBE 223.13 Adtran ADTN 10.82 Aduro Biotech ADRO 2.65 Advanced Emissions Solutions ADES 10.07 Advanced Energy Industries AEIS 42.71 Advanced Micro Devices AMD 17.82 Advaxis ADXS 0.19 Adverum Biotechnologies ADVM 3.2 Aegion AEGN 16.24 Aeglea BioTherapeutics AGLE 7.67 Aemetis AMTX 0.57 Aerie Pharmaceuticals AERI 35.52 AeroVironment AVAV 67.57 Aevi Genomic Medicine GNMX 0.67 Affimed AFMD 3.11 Agile Therapeutics AGRX 0.61 Agilysys AGYS 14.59 Agios Pharmaceuticals AGIO 45.3 AGNC Investment AGNC 17.73 AgroFresh Solutions AGFS 3.85
  • Market Cap Close ADV

    Market Cap Close ADV

    Market Cap Close ADV 1598 67th Pctl $745,214,477.91 $23.96 225,966.94 801 33rd Pctl $199,581,478.89 $10.09 53,054.83 2399 Listing_ Revised Ticker_Symbol Security_Name Exchange Effective_Date Mkt Cap Close ADV Stratum Stratum AAC AAC Holdings, Inc. N 20160906 M M M M-M-M M-M-M Altisource Asset Management AAMC Corp A 20160906 L M L L-M-L L-M-L AAN Aarons Inc N 20160906 H H H H-H-H H-H-H AAV Advantage Oil & Gas Ltd N 20160906 H L M H-L-M H-M-M AB Alliance Bernstein Holding L P N 20160906 H M M H-M-M H-M-M ABG Asbury Automotive Group Inc N 20160906 H H H H-H-H H-H-H ABM ABM Industries Inc. N 20160906 H H H H-H-H H-H-H AC Associated Capital Group, Inc. N 20160906 H H L H-H-L H-H-L ACCO ACCO Brand Corp. N 20160906 H L H H-L-H H-L-H ACU Acme United A 20160906 L M L L-M-L L-M-L ACY AeroCentury Corp A 20160906 L L L L-L-L L-L-L ADK Adcare Health System A 20160906 L L L L-L-L L-L-L ADPT Adeptus Health Inc. N 20160906 M H H M-H-H M-H-H AE Adams Res Energy Inc A 20160906 L H L L-H-L L-H-L American Equity Inv Life Hldg AEL Co N 20160906 H M H H-M-H H-M-H AF Astoria Financial Corporation N 20160906 H M H H-M-H H-M-H AGM Fed Agricul Mtg Clc Non Voting N 20160906 M H M M-H-M M-H-M AGM A Fed Agricultural Mtg Cla Voting N 20160906 L H L L-H-L L-H-L AGRO Adecoagro S A N 20160906 H L H H-L-H H-L-H AGX Argan Inc N 20160906 M H M M-H-M M-H-M AHC A H Belo Corp N 20160906 L L L L-L-L L-L-L ASPEN Insurance Holding AHL Limited N 20160906 H H H H-H-H H-H-H AHS AMN Healthcare Services Inc.
  • Foreign Private Issuers Lists, 1996

    Foreign Private Issuers Lists, 1996

    u.s. Securities and Exchange Commission FOREIGN COMPANIES REGISTERED AND REPORTING WITH THE u.S. SECURITIES AND EXCHANGE COMMISSION DECEMBER 31 , 1996 Office of International Corporate Finance Division of Corporation Finance REPORTING FOREIGN ISSUERS AS OF DECEMBER 31, 1996 SUMMARY"INFORMATION REPORTING COUNTRY COMPANIES CANADA 374 UNITED KINGDOM 81 ISRAEL 71 MEXICO 30 NETHERLANDS 29 AUSTRALIA 26 BERMUDA 22 CHILE 22 JAPAN 21 FRANCE 18 ITALY 13 ARGENTINA 12 BRITISH VIRGIN ISLANDS 11 IRELAND 11 SWEDEN 10 INDONESIA 9 GERMANY 8 LUXEMBOURG 8 SPAIN 8 NETHERLANDS ANTILLES 7 NORWAY 7 BAHAMAS 6 SOUTH AFRICA 6 CHINA 5 FINLAND 5 HONG KONG 5 LIBERIA 5 BRAZIL 4 CAYMAN ISLANDS 4 COLOMBIA 4 DENMARK 4 KOREA 4 NEW ZEALAND 4 VENEZUELA 4 PERU 3 PORTUGAL 3 SINGAPORE 3 BELGIUM 2 PANAMA 2 PHILIPPINES 2 BELIZE 1 BOTSWANA 1 GHANA 1 PAPUA NEW Gl.!lNEA 1 RUSSIA 1 SWITZERLAND 1 TAIWAN 1 ZAMBIA 1 TOTAL 881 p MARKET SUMMARY BY COUNTRY NASDAQ NASDAQ COUNTRY NYSE AMEX NMS Small Cap OTC COMBINED ARGENTINA 10 0 1 0 1 12 26 AUSTRALIA 9 0 7 3 7 BAHAMAS 1 0 2 0 3 6 BELGIUM 0 0 2 0 0 2 BELIZE 0 0 1 0 0 1 BERMUDA 9 3 7 1 2 22 BOTSWANA 0 0 0 0 1 1 4 BRAZIL 2 0 1 0 1 BRIT. V.1. 0 0 8 1 2 11 CANADA 61 39 94 57 123 374 CAYMAN ISLANDS 0 2 2 0 0 4 CHILE 19 0 1 0 2 22 CHINA 5 0 0 0 0 5 COLOMBIA 2 0 0 0 2 4 DENMARK 3 0 1 0 0 4 FINLAND 3 '0 0 1 1 5 FRANCE 9 0 6 0 3 18 GERMANY 5 0 1 0 2 8 GHANA 1 0 0 0 0 1 HONG KONG 1 0 0 0 4 5 0 4 9 I INDONESIA 4 0 1 IRELAND 5 0 3 1 2 11 ISRAEL 4 5 45 11 6 71 ITALY 11 0 2 0 0 13 JAPAN 11 0 7 1 2 21 KOREA 3 0 0 0 1 4 LIBERIA 2 2 0 0 1 5 LUXEMBOURG 3 0 5 0 0 8 MEXICO 25 2 0 0 3 30 NETH.
  • Alphabetical Listing by Company Name

    Alphabetical Listing by Company Name

    FOREIGN COMPANIES REGISTERED AND REPORTING WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION December 31, 2015 Alphabetical Listing by Company Name COMPANY COUNTRY MARKET 21 Vianet Group Inc. Cayman Islands Global Market 37 Capital Inc. Canada OTC 500.com Ltd. Cayman Islands NYSE 51Job, Inc. Cayman Islands Global Market 58.com Inc. Cayman Islands NYSE ABB Ltd. Switzerland NYSE Abbey National Treasury Services plc United Kingdom NYSE - Debt Abengoa S.A. Spain Global Market Abengoa Yield Ltd. United Kingdom Global Market Acasti Pharma Inc. Canada Capital Market Acorn International, Inc. Cayman Islands NYSE Actions Semiconductor Co. Ltd. Cayman Islands Global Market Adaptimmune Ltd. United Kingdom Global Market Adecoagro S.A. Luxembourg NYSE Adira Energy Ltd. Canada OTC Advanced Accelerator Applications SA France Global Market Advanced Semiconductor Engineering, Inc. Taiwan NYSE Advantage Oil & Gas Ltd. Canada NYSE Advantest Corp. Japan NYSE Aegean Marine Petroleum Network Inc. Marshall Islands NYSE AEGON N.V. Netherlands NYSE AerCap Holdings N.V. Netherlands NYSE Aeterna Zentaris Inc. Canada Capital Market Affimed N.V. Netherlands Global Market Agave Silver Corp. Canada OTC Agnico Eagle Mines Ltd. Canada NYSE Agria Corp. Cayman Islands NYSE Agrium Inc. Canada NYSE AirMedia Group Inc. Cayman Islands Global Market Aixtron SE Germany Global Market Alamos Gold Inc. Canada NYSE Alcatel-Lucent France NYSE Alcobra Ltd. Israel Global Market Alexandra Capital Corp. Canada OTC Alexco Resource Corp. Canada NYSE MKT Algae Dynamics Corp. Canada OTC Algonquin Power & Utilities Corp. Canada OTC Alianza Minerals Ltd. Canada OTC Alibaba Group Holding Ltd. Cayman Islands NYSE Allot Communications Ltd. Israel Global Market Almaden Minerals Ltd.
  • ISRAEL Global Center for Breakthrough

    ISRAEL Global Center for Breakthrough

    ISRAEL Global Center for Breakthrough www.investinisrael.gov.il Bright Source Dear Reader, Israel is recognized as being Israel’s ability to continuously produce high- at the forefront of high- quality innovative products is fundamental to tech innovation, backed by a its capacity to compete globally and the Israeli highly educated and creative government considers it a high priority to ensure workforce and a sound and support Israel’s future competitiveness. infrastructure. Some of the I am confident that the vitality of the Israeli market world’s largest multinational will continue to position it as a global destination corporations developed their for foreign investment and invite you to take part key breakthroughs in Israel, in our future expansion. and the ongoing influx of new companies serve as a sign of the vibrancy of Israel’s industrial research and development. Israel enjoys the highest percentage in the world Sincerely, of engineers in the workforce and one of the Binyamin (Fouad) Ben Eliezer – highest ratios of university degrees and academic publications per capita. Israel’s finest innovations were developed through the combination of necessity, proven problem solving skills and creativity. Due to the close-knit web of Israeli society, the synergetic nature of Israeli industry Minister of Industry, Trade and Labor allows for cross-sectoral adaptations of technology from the security sector to life sciences, IT and communications. Highly trained graduates of the IDF applied cutting edge defense technology to market-changing civilian applications. 3 Intel Dear Investor, Israeli Innovations Israel has a long track record of An ability to quickly respond to market demands market-creating, profit driving and identify future needs as well as to determine Merging Necessity & Ingenuity Striving for SUCCESS breakthrough innovations and provide solutions to global needs across which have positively impacted different sectors; The technological skill of Israeli life worldwide.
  • Development of Computed Tomography

    Development of Computed Tomography

    Case Histories of Significant Medical Advances: Development of Computed Tomography Amar Bhidé Srikant Datar Katherine Stebbins Working Paper 20-004 Case Histories of Significant Medical Advances: Development of Computed Tomography Amar Bhidé Harvard Business School Srikant Datar Harvard Business School Katherine Stebbins Harvard Business School Working Paper 20-004 Copyright © 2019, 2020, 2021 by Amar Bhidé and Srikant Datar Working papers are in draft form. This working paper is distributed for purposes of comment and discussion only. It may not be reproduced without permission of the copyright holder. Copies of working papers are available from the author. Case Histories of Significant Medical Advances Development of Computed Tomography Amar Bhidé, Harvard Business School Srikant Datar, Harvard Business School Katherine Stebbins, Harvard Business School Abstract: We describe how Computed Tomography (CT) scanners - that combine x-rays and computers to image soft tissues of the brain and other organs -- have become a widely used diagnostic tool. Specifically, we chronicle the: 1) the initial development of CT technology and markets (in the 1960s and 1970s); 2) Broadening of uses and users (in the 1980s); and 3) introduction and adoption of combination scanners (in the 1990s). Note: This case history, like the others in this series, is included in a list compiled by Victor Fuchs and Harold Sox (2001) of technologies produced (or significantly advanced) between 1975 and 2000 that internists in the United States said had had a major impact on patient care. The case histories focus on advances in the 20th century (i.e., before this millennium) in the United States, Europe, and Japan -- to the degree information was available to the researchers.
  • Israel's High-Tech Figures

    Israel's High-Tech Figures

    High-Tech Industries Israel’s High-Tech Figures Israel has become one of the world’s most highly regarded and 2001. He joined the company in 1994, and is serving as a director important high-tech centers and high-tech is the main growth in some of Elron's subsidiaries. engine of Israel’s economy. In 2004, Israeli high-tech sales exceeded $15 billion, including $12.9 billion in exports. In the Davidi Gilo – One of the most important inventors and peak year of 2000, no less than 3,000 high-tech start-ups were entrepreneurs of the Israeli high-tech industry. Gilo is also the active in Israel – one start-up per 2,000 residents. man responsible for one of biggest high-tech deals in Israeli history – the purchase of DSPC (DSP Communications), a This chapter presents the figures standing behind the impressive wireless communications chip designer, by Intel (1999), in a deal activities of Israel’s high-tech industries. Israel’s high-tech worth $1.6 billion. community is characterized by a high concentration of talent, Gilo established the DSPC Group in the United States, but its energy and innovation. We’ve chosen to focus on a number R&D centers were located in Israel. of issues important to Israeli high-tech, featuring some of the personalities. Benny Peled (deceased) – Major General (Res.) Benny Peled, former Commander of the Israeli Air Force (1973-1977), Founding Fathers served as president of Elbit and its subsidiary Elscint. Peled turned Elbit into one of the most important providers of defense Efi Arazi – The “wonder kid” of the Israeli economy, is best systems and equipment in Israel and abroad.
  • NOVA MEASURING INSTRUMENTS LTD. (Exact Name of Registrant As Specified in Its Charter)

    NOVA MEASURING INSTRUMENTS LTD. (Exact Name of Registrant As Specified in Its Charter)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 20-F o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR o TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o SHELL COMPANY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-30668 NOVA MEASURING INSTRUMENTS LTD. (Exact name of Registrant as specified in its charter) Nova Measuring Instruments Ltd. Israel (Translation of Registrant’s name into English) (Jurisdiction of incorporation or organization) Weizmann Science Park, Einstein St., Building 22, 2nd Floor, Ness-Ziona, Israel (Address of principal executive offices) Dror David, +972-73-2295833, +972-8-9407776, P.O.B 266, Rehovot 7610201, Israel (Name, Telephone, E-mail and/or Facsimile number and Address of the Registrant’s Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which registered Ordinary Shares, nominal value NIS 0.01 per share The NASDAQ Global Select Market Securities registered or to be registered pursuant to Section 12(g) of the Act: None Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report: 27,351,431 ordinary shares, NIS 0.01 nominal (par) value per share, as of December 31, 2016.
  • Ticker Name Sector Subgroup Market Cap Price P/E Gryld ESLT ELBIT SYSTEMS LTD Aerospace/Defense Aerospace/Defense-Equip 1872732

    Ticker Name Sector Subgroup Market Cap Price P/E Gryld ESLT ELBIT SYSTEMS LTD Aerospace/Defense Aerospace/Defense-Equip 1872732

    Ticker Name Sector Subgroup Market Cap Price P/E GrYld ESLT ELBIT SYSTEMS LTD Aerospace/Defense Aerospace/Defense-Equip 1872732000 43.72 10.16 3.29 TATT TAT TECHNOLOGIES LTD Aerospace/Defense Aerospace/Defense-Equip 44163170 5.01 N/A N/A DELTY DELTA GALIL INDUSTRIES-ADR Apparel Apparel Manufacturers 132338700 5.65 N/A 6.01 CGEN COMPUGEN LTD Biotechnology Medical-Biomedical/Gene 142664900 4.16 N/A N/A PNTR POINTER TELOCATION LTD Commercial Services Commercial Services 19191250 4.01 11.46 N/A LAXAF LAXAI PHARMA LTD Commercial Services Research&Development 570408.8 0.01 N/A N/A BPHX BLUEPHOENIX SOLUTIONS LTD Computers Computer Services 15623440 0.63 N/A N/A JCDA JACADA LTD Computers Computer Services 9037805 2.25 N/A N/A TISA TOP IMAGE SYSTEMS LTD Computers Computers-Integrated Sys 17851280 2.00 18.18 N/A ELTK ELTEK LTD Electronics Circuit Boards 6940612 1.05 N/A N/A ELRNF ELRON ELECTRONIC INDS LTD Electronics Electronic Compo-Misc 122792500 4.14 N/A N/A RADA RADA ELECTRONIC INDS LTD Electronics Electronic Compo-Misc 19954930 2.25 12.50 N/A ORBK ORBOTECH LTD Electronics Electronic Measur Instr 444145500 10.31 7.26 N/A CAMT CAMTEK LTD Electronics Electronic Measur Instr 56486220 1.98 6.83 N/A ITRN ITURAN LOCATION AND CONTROL Electronics Electronic Secur Devices 258956200 12.35 N/A 8.10 MAGS MAGAL SECURITY SYS LTD Electronics Electronic Secur Devices 37967580 2.40 N/A N/A OTIV ON TRACK INNOVATIONS LTD Electronics Identification Sys/Dev 45468330 1.46 N/A N/A BSI ALON HOLDINGS BLUE SQ-ADR Food Food-Retail 342303500 5.19 N/A N/A WILC G.
  • INVESTOR PRESENTATION March 2021 This Presentation Is for Information Purposes Only

    INVESTOR PRESENTATION March 2021 This Presentation Is for Information Purposes Only

    ELRON - INVESTOR PRESENTATION March 2021 This presentation is for information purposes only. By this presentation, Elron does not intend to solicit offers to purchase its securities and the presentation does not constitute an invitation to receive such offers, and nothing said therein constitutes a “public offering”, as defined in the Israel Securities Law, 5728-1968. Elron may make improvements and/or changes in the features or content presented herein at any time. Elron shall not be liable for COMMENTS any loss, claim, liability or damage of any kind resulting from the investor's reliance on or reference to any detail, fact or opinion presented herein. The presentation is not intended to provide a comprehensive description of Elron's activities, and Elron urges investors to consider the information presented herein in conjunction with its public filings including its annual and other periodic reports. Nothing in this presentation should be considered "investment advice", as defined in the Israel Regulation of Investment Advice, Investment Marketing and Portfolio Management Law, 5755-1995. Certain statements made over the course of this presentation may be forward-looking in nature, as defined in Section 32A of the Israel Securities Law, 5728-1968. Such forward-looking statements involve known and unknown risks, uncertainties, forecasts, assessments, estimates or other information, which relates to a future event or matter whose occurrence is not certain and which is not within the sole control of Elron, and other factors which may cause the actual results, performance and achievements of Elron to be materially different from any future results, performance and achievements implied by such forward-looking statements.